Abstract: Our findings demonstrate that Ursolic acid (UA) attenuates microglial pyroptosis by inhibiting NF-κB signaling, thereby reducing neuroinflammation and ischemic brain injury. This study highlights UA's potential as a therapeutic agent for ischemic stroke.
Introduction
Ischemic stroke is a leading cause of global disability and mortality. While the restoration of blood flow (reperfusion) is the primary clinical goal, it often triggers a secondary cascade of damage known as cerebral ischemia-reperfusion injury (CIRI). A central driver of CIRI is the overactivation of microglia, the brain's resident immune cells. These cells can undergo a highly inflammatory form of programmed cell death called pyroptosis.
Unlike the more controlled process of apoptosis, pyroptosis involves the activation of the NLRP3 inflammasome, which recruits Caspase-1 to cleave Gasdermin D (GSDMD). This protein then forms pores in the cell membrane, causing the cell to burst and release pro-inflammatory cytokines like IL-1β and IL-18, which exacerbate neuronal damage. This study investigates the protective effects of Ursolic acid (UA), a natural pentacyclic triterpenoid, against this inflammatory cascade.
Methods
The researchers employed both in vivo and in vitro models to evaluate UA's efficacy:
- In Vivo Model: Transient middle cerebral artery occlusion (tMCAO) was performed on adult male C57BL/6 mice to simulate stroke and reperfusion. UA was administered orally for seven days at varying doses.
- In Vitro Model: BV-2 microglial cells were subjected to oxygen-glucose deprivation/reoxygenation (OGD/R) to mimic ischemic conditions in a laboratory setting.
- Mechanistic Analysis: To confirm the pathway, the team used PMA, a potent NF-κB agonist, to see if it could reverse the protective effects of UA.
- Evaluation Metrics: Brain damage was assessed via TTC staining (infarct volume), TUNEL and FJC staining (neuronal death), and behavioral assessments including the Open Field and Novel Object Recognition tests.
Results
Reduction of Brain Infarction and Neuronal Death
Treatment with UA significantly mitigated the physical and cellular damage caused by ischemia. Mice treated with UA showed a dose-dependent reduction in brain infarct volume compared to the untreated tMCAO group. Furthermore, UA treatment led to a dramatic decrease in the number of TUNEL-positive (apoptotic) and FJC-positive (degenerating) neurons in the penumbra, the vulnerable area surrounding the stroke core.
Inhibition of the NF-κB/NLRP3 Axis
The study identified that UA acts as a potent inhibitor of the NF-κB signaling pathway. By preventing the translocation of NF-κB into the nucleus, UA stops the transcription of NLRP3 inflammasome components. This inhibition prevents the cleavage of GSDMD, effectively halting the pyroptotic process. In cell models, UA restored microglial viability that had been halved by OGD/R conditions.
Functional and Behavioral Recovery
Beyond cellular protection, UA treatment translated into improved functional outcomes. Mice receiving UA exhibited better memory retention and reduced anxiety-like behaviors in behavioral tests, suggesting that the reduction in neuroinflammation directly supports neurological recovery.
Discussion and Mechanistic Insights
The core finding of this research is the identification of NF-κB as the primary molecular target for UA's anti-inflammatory action. By flipping this "master switch" to the off position, UA prevents the assembly of the NLRP3 inflammasome and the subsequent release of inflammatory "firebrands" like IL-1β and IL-18. The use of the agonist PMA confirmed this; when NF-κB was artificially reactivated, the protective benefits of UA were lost, proving the pathway's necessity.
Conclusion and Future Directions
Ursolic acid shows significant promise as a therapeutic candidate for ischemic stroke by specifically targeting microglial pyroptosis via the NF-κB/NLRP3 pathway. However, the authors note that future work is needed to identify the exact protein targets UA binds to and to determine if UA offers direct protection to neurons or if its benefits are primarily mediated through its effects on microglia. Additionally, moving from immortalized cell lines to primary microglial cultures will be a critical next step for clinical relevance.
Summary updated